Recent News

Dying for an MRI – 7 News Investigation

Dying for an MRI – 7 News Investigation (WSVN 7 Fox News Miami/Fort Lauderdale)

Parker Waichman LLP Files Suit Against Bayer-Schering

Parker Waichman LLP Files Suit Against Bayer-Schering on Behalf of Woman Who Developed Nephrogenic Systemic Fibrosis (NSF) from Contrast Agent Magnevist

Read More

9/9/10-FDA Stregnthens Warnings on Gadolinium MRI Dyes

Gadolinium-based contrast dyes will now bear new warnings on their labels regarding their association with nephrogenic systemic fibrosis (NSF), according to the Food & Drug Administration (FDA). Gadolinium-based contrast dyes are intravenous drugs approved by the FDA for use with magnetic resonance imaging (MRI) or magnetic resonance angiography (MRA) to help detect

Read More

FDA Gadolinium Warning 5/23/07

n May 2007, the FDA requested that the manufacturers of the five gadolinium based contrast agents used in MRIs include a boxed warning – the FDA’s strongest possible safety warning – on product labels highlighting the risk they posed to patients with kidney problems. The FDA warned that patients who are at risk for NSF should be monitored by their doctors, and told to report any symptoms associated

Read More

FDA Gadolinium Warning 12/22/06

In December of 2006, the FDA issued its second public health advisory regarding gadolinium based contrast dyes. At that time, the FDA said it had received 90 reports of patients with moderate to end-stage kidney disease who developed NSF after being exposed to gadolinium based contrast agents. At the time of this alert, the FDA said about 215 patients worldwide were known

Read More

FDA Gadolinium Warning 6/08/06

In June 2006, the Food & Drug Administration (FDA) issued what would be the first of three warnings on gadolinium contrast dyes. Following the publication of the Dutch NSF study in 2006, the FDA issued an alert to healthcare providers that gadolinium based agents had been tied to multiple cases of NSF. Although these cases were not limited to one gadolinium based contrast agent, three were most often associated with the onset of NSF. Those three were Ominiscan, Magnevist and OptiMark. At that time the FDA warned

Read More

Gadolinium MRA Contrast Side Effect Injuries

Gadolinium MRA contrast dye is used in Magnetic Resonance Imaging (MRA) so that diagnosticians can more easily differentiate between normal and abnormal tissue. Unfortunately, Gadolinium MRA contrast dye has been linked to a serious condition called Nephrogenic Systemic Fibrosis (NSF) and Nephrogenic Fribrosing Dermopathy (NSD). This serious and sometimes fatal Gadolinium side effect is seen in patients with

Read More

Gadolinium Linked to Nephrogenic Systemic Fibrosis (NSF) and Nephrogenic Fibrosing Dermopathy (NFD)

Since 1997, medical science has been trying to solve the mystery of NSF/NSD. But until recently, little was known about the causes of NSF/NSD and even less about its treatment. However, in 2006 research into NSF/NSD finally yielded some results. In a study conducted by Dr. T. Grobner, it was found that of 9 people with NSF/NSD, 5 of the

Read More

Legal Assistance form NSF and NFD Sufferers Who Had an MRA with Gadolinium Contrast Dye

If you or a loved one believes you developed NSF/NSD from a gadolinium based contrast agent, you have valuable legal rights. Please fill out the form at the left for a free case evaluation or call 1-800-LAW-INFO (1-800-529-4636).

Martindale-Hubbell - Peer Review Rated

Martindale-Hubbell - Peer Review Rated

Read More